Comparative Pharmacology
Head-to-head clinical analysis: PROKETAZINE versus TRILAFON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROKETAZINE versus TRILAFON.
PROKETAZINE vs TRILAFON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.
Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.
25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.
8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is approximately 10–20 hours (mean ~12 hours); supports twice-daily dosing.
Primarily renal excretion of metabolites; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 20% of total clearance.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for the majority of elimination.
Category C
Category C
Phenothiazine Antipsychotic
Phenothiazine Antipsychotic